$4.03
4.50% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US50015M1099
Symbol
KOD
Sector
Industry

Kodiak Sciences, Inc. Stock price

$4.03
-0.10 2.42% 1M
-4.91 54.92% 6M
-5.92 59.50% YTD
+1.21 42.91% 1Y
-54.93 93.16% 5Y
-6.13 60.33% 10Y
-6.13 60.33% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.19 4.50%
ISIN
US50015M1099
Symbol
KOD
Sector
Industry

Key metrics

Market capitalization $212.64m
Enterprise Value $73.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.95
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-197.97m
Free Cash Flow (TTM) Free Cash Flow $-107.44m
Cash position $138.85m
EPS (TTM) EPS $-3.62
P/E forward negative
Short interest 10.33%
Show more

Is Kodiak Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Kodiak Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Kodiak Sciences, Inc. forecast:

1x Buy
20%
1x Hold
20%
3x Sell
60%

Analyst Opinions

5 Analysts have issued a Kodiak Sciences, Inc. forecast:

Buy
20%
Hold
20%
Sell
60%

Financial data from Kodiak Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
16% 16%
-
- Research and Development Expense 140 140
22% 22%
-
-169 -169
26% 26%
-
- Depreciation and Amortization 29 29
50% 50%
-
EBIT (Operating Income) EBIT -198 -198
20% 20%
-
Net Profit -191 -191
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kodiak Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kodiak Sciences, Inc. Stock News

Neutral
PRNewsWire
13 days ago
PALO ALTO, Calif. , May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.
Neutral
PRNewsWire
29 days ago
PALO ALTO, Calif. , May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025.
Neutral
PRNewsWire
about one month ago
PALO ALTO, Calif. , May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) ...
More Kodiak Sciences, Inc. News

Company Profile

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Head office United States
CEO Victor Perlroth
Employees 109
Founded 2009
Website kodiak.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today